ArticleAntimicrobial agents and chemotherapy2023
Plasmid genomic epidemiology of
Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Antimicrobial resistance and plasmidome of carbapenemase-resistant Klebsiella pneumoniae causing bloodstream infections between 2014 and 2024.BMC microbiology · 2026Article
- Article
- IncL plasmid-mediated dissemination of OXA-48 β-lactamase andJAC-antimicrobial resistance · 2026Article
- Community-associated Carbapenem-Resistant Organism Case Investigations in New York City.Open forum infectious diseases · 2025Article
- Integrated Sample to Detection of Carbapenem-Resistant Bacteria Extracted from Water Samples Using a Portable Gold Nanoparticle-Based Biosensor.Sensors (Basel, Switzerland) · 2025Article
- Plasmid genomic epidemiology ofMicrobial genomics · 2025Article
- Potential role of avibactam in restoring susceptibility in Escherichia coli with two copies of blaScientific reports · 2025Article
- Review
- The dark matter of bacterial genomic surveillance-antimicrobial resistance plasmid transmissions in the hospital setting.Journal of clinical microbiology · 2025Article
- Dissemination of IncQ1 Plasmids Harboring NTEMicroorganisms · 2025Article
- Article
- The characterization of an IncN-IncR fusion plasmid co-harboring blaScientific reports · 2024Article
- Plasmid genomic epidemiology of carbapenem-hydrolysing class D β-lactamase (CDHL)-producingMicrobial genomics · 2024Article
- Hybracter: enabling scalable, automated, complete and accurate bacterial genome assemblies.Microbial genomics · 2024Article
- Hybracter: Enabling Scalable, Automated, Complete and Accurate Bacterial Genome Assemblies.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 16 institutions in 1 country.
Funding
Abstract
Carbapenems are considered last-resort antibiotics for the treatment of infections caused by multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.